CapitalBio | GenomeWeb

CapitalBio

Fluidigm of South San Francisco, Calif., has received US Patent No.

CapitalBio and Tsinghua University of Beijing have received US Patent No.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

NEW YORK (GenomeWeb News) – Chinese life science company CapitalBio will solidify its efforts to become a major laboratory testing player in the country's clinical and consumer genetics markets by opening a new facility next year.

By law, Chinese samples cannot leave China. That fact has made Shanghai Biochip a partner for international pharmaceutical companies seeking to conduct various trials in the country.

BEIJING — Like many microarray vendors, CapitalBio sees future growth opportunities in molecular diagnostics.

CapitalBio and Tsinghua University, both of Beijing, have received US Patent No.

This article has been updated from a version posted Feb. 16 to include comments from an Affymetrix official.
By Justin Petrone

IP Roundup

Premium

Anagnostics, SRU Biosystems, Affymetrix, CapitalBio

Roche NimbleGen will work with Beijing-based CapitalBio to develop instruments and products to enhance and automate its microarray workflow for use in preventive and personalized diagnostics.

Pages

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.